Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
August 09 2023 - 7:00AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the Month of August 2023
Commission File Number 001-35948
Kamada Ltd.
(Translation of registrant’s name into English)
2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference
into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720,
333-207933, 333-215983,
333-222891, 333-233267
and 333-265866.
The following exhibit is attached:
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 9, 2023 |
KAMADA LTD. |
|
|
|
By: |
/s/ Nir Livneh |
|
|
Nir Livneh
Vice President General Counsel and
Corporate Secretary |
EXHIBIT INDEX
3
Exhibit 99.1
Kamada to Announce Second Quarter and First
Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023
Rehovot, Israel, and Hoboken, NJ, August 9,
2023 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products
indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial
results for the second quarter and first half ended June 30, 2023, prior to the open of the U.S. financial markets on Wednesday, August
16, 2023.
Kamada management will host an investment community
conference call on Wednesday, August 16, 2023 at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other
interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel)
or 1 201-689-8263 (International) using conference ID 13740401. The call will also be webcast live on the Internet at: https://viavid.webcasts.com/starthere.jsp?ei=1626943&tp_key=6e37fa90e3.
The call
will also be archived for 90 days on the Company’s website at www.kamada.com.
About Kamada
Kamada Ltd. (the “Company”) is a commercial
stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in
the specialty plasma-derived field, focused on diseases of limited treatment alternatives. The Company is also advancing an innovative
development pipeline targeting areas of significant unmet medical need. The Company’s strategy is focused on driving profitable
growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical
fields. The Company’s commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products: CYTOGAM®,
KEDRAB®, WINRHO SDF®, VARIZIG®, HEPAGAM B® and GLASSIA®, as well as KAMRAB®, KAMRHO (D)® and two types of
equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic
partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India,
Australia and other countries in Latin America, Europe, Middle East, and Asia. The Company leverages its expertise and presence in the
Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers.
During recent years the Company added eleven biosimilar products to its Israeli distribution portfolio, which, subject to the European
Medicines Agency (EMA) and the Israeli Ministry of Health approvals, are expected to be launched in Israel through 2028. The Company owns
an FDA licensed plasma collection center in Beaumont, Texas, which currently specializes in the collection of hyper-immune plasma used
in the manufacture of KAMRHO (D). In addition to the Company’s commercial operation, it invests in research and development of new
product candidates. The Company’s leading investigational product is an inhaled AAT for the treatment of AAT deficiency, for which
it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI
Opportunity Funds, the leading private equity firm in Israel, is the Company’s lead shareholder, beneficially owning approximately
21% of the outstanding ordinary shares.
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
(212) 915-2578
britchie@LifeSciAdvisors.com
Kamada (NASDAQ:KMDA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Kamada (NASDAQ:KMDA)
Historical Stock Chart
From Aug 2023 to Aug 2024